// App-Quantinova.ai

6531 : BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the second-generation TKI era.

Researchers

Presenter

  • Simona Soverini

Principal Investigators

  • Alessandra Gnani

  • Caterina De Benedittis

  • Marzia Salvucci

  • Antonella Vitale

  • Loredana Elia

  • Marco Vignetti

  • Robin Foa

  • Michele Baccarani

  • Giovanni Martinelli

  • Ilaria Iacobucci

  • Claudia Venturi

  • Cristina Papayannidis

  • Mario Luppi

  • Serena Merante

  • Michele Malagola

  • Domenico Russo

  • Mario Tiribelli

Medical Centers

  • Hematology, Ospedale Santa Maria delle Croci, Ravenna, Italy

  • Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy

  • Gimema Data Center, Rome, Italy

  • Hematology, University of Brescia, Brescia, Italy

  • Division of Hematology, Department of Oncohematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

  • Univeristy of Bologna, Bologna, Italy

  • Division of Hematology, Department of Clinical and Morphological Researches, University of Udine, Udine, Italy

  • Division of Hematology, Department of Cellular Biotechnologies and Hematology, Hematology, Sapienza University of Rome, Rome, Italy

  • Department of Hematology/Oncology Seragnoli, Bologna, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved